Payment overview · 2025
General Payments
$191.47
9 reported records · 6 companies
Healthcare provider profile · identity verified
Oscar Mendez, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAUDERHILL, FL · NPI 1164520243
Verified facts
What the public records show
CMS Open Payments records show Oscar Mendez, MD received $191.47 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 391 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.03 | 30.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.63 | 21.7% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $36.59 | 19.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.79 | 10.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.82 | 9.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.61 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $191.47 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.63 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $36.59 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
391 | 83 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
204 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1342 | 422 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1264 | 412 |
| Folic Acid | Folic Acid | 1192 | 414 |
| Amlodipine Besylate | Amlodipine Besylate | 915 | 308 |
| Metformin Hcl | Metformin Hcl | 798 | 260 |
| Pantoprazole Sodium | Pantoprazole Sodium | 621 | 220 |
| Losartan Potassium | Losartan Potassium | 543 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 527 | 159 |
| Hydrochlorothiazide | Hydrochlorothiazide | 496 | 161 |
| Lisinopril | Lisinopril | 485 | 154 |
| Metoprolol Tartrate | Metoprolol Tartrate | 453 | 144 |
| Omeprazole | Omeprazole | 433 | 158 |
| Gabapentin | Gabapentin | 431 | 141 |
| Farxiga | Dapagliflozin Propanediol | 391 | 83 |
| Alendronate Sodium | Alendronate Sodium | 371 | 126 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 349 | 160 |
| Temazepam | Temazepam | 311 | 52 |
| Alprazolam | Alprazolam | 309 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 309 | 113 |
| Tamsulosin Hcl | Tamsulosin Hcl | 289 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 282 | 102 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 277 | 84 |
| Famotidine | Famotidine | 267 | 93 |
| Glipizide | Glipizide | 262 | 88 |
| Carvedilol | Carvedilol | 259 | 78 |
| Montelukast Sodium | Montelukast Sodium | 257 | 97 |
| Clopidogrel | Clopidogrel Bisulfate | 228 | 68 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 228 | 139 |
| Trazodone Hcl | Trazodone Hcl | 224 | 62 |
| Eliquis | Apixaban | 204 | 51 |
| Sertraline Hcl | Sertraline Hcl | 201 | 57 |
| Simvastatin | Simvastatin | 200 | 59 |
| Furosemide | Furosemide | 197 | 81 |
| Azithromycin | Azithromycin | 191 | 153 |
| Ibuprofen | Ibuprofen | 188 | 74 |
| Tramadol Hcl | Tramadol Hcl | 188 | 56 |
| Jardiance | Empagliflozin | 177 | 47 |
| Naproxen | Naproxen | 176 | 73 |
| Potassium Chloride | Potassium Chloride | 175 | 66 |
| Latanoprost | Latanoprost | 172 | 42 |
| Nifedipine Er | Nifedipine | 166 | 57 |
| Meloxicam | Meloxicam | 162 | 63 |
| Donepezil Hcl | Donepezil Hcl | 152 | 57 |
| Enalapril Maleate | Enalapril Maleate | 146 | 43 |
| Allopurinol | Allopurinol | 142 | 55 |
| Glimepiride | Glimepiride | 142 | 47 |
| Valsartan | Valsartan | 142 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 141 | 42 |
| Atenolol | Atenolol | 133 | 45 |
| Januvia | Sitagliptin Phosphate | 125 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 124 | 35 |
| Finasteride | Finasteride | 122 | 39 |
| Mupirocin | Mupirocin | 122 | 61 |
| Prednisone | Prednisone | 122 | 64 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 121 | 104 |
| Sildenafil Citrate | Sildenafil Citrate | 119 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 36 |
| Ozempic | Semaglutide | 112 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 108 | 37 |
| Glipizide Er | Glipizide | 105 | 36 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 102 | 49 |
| Xarelto | Rivaroxaban | 102 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 42 |
| Fluconazole | Fluconazole | 94 | 74 |
| Celecoxib | Celecoxib | 91 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 29 |
| Spironolactone | Spironolactone | 88 | 34 |
| Entresto | Sacubitril/Valsartan | 84 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | 38 |
| Meclizine Hcl | Meclizine Hcl | 83 | 44 |
| Trulicity | Dulaglutide | 83 | 20 |
| Megestrol Acetate | Megestrol Acetate | 82 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 81 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 80 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 79 | 26 |
| Clonazepam | Clonazepam | 78 | 15 |
| Tradjenta | Linagliptin | 76 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 22 |
| Lorazepam | Lorazepam | 75 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 70 | 21 |
| Memantine Hcl | Memantine Hcl | 70 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 24 |
| Ezetimibe | Ezetimibe | 69 | 24 |
| Nabumetone | Nabumetone | 69 | 30 |
| Repaglinide | Repaglinide | 65 | 22 |
| Labetalol Hcl | Labetalol Hcl | 64 | 19 |
| Ketoconazole | Ketoconazole | 63 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 19 |
| Lovastatin | Lovastatin | 55 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | 16 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 53 | 25 |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Fenofibrate | Fenofibrate | 51 | 15 |
| Pregabalin | Pregabalin | 51 | 16 |
| Lactulose | Lactulose | 50 | suppressed |
| Baclofen | Baclofen | 49 | 14 |
| Clonidine Hcl | Clonidine Hcl | 49 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 18 |
| Levetiracetam | Levetiracetam | 48 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 20 |
| Ondansetron Odt | Ondansetron | 44 | 27 |
| Mirtazapine | Mirtazapine | 43 | 15 |
| Rybelsus | Semaglutide | 43 | 13 |
| Ammonium Lactate | Ammonium Lactate | 42 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 14 |
| Irbesartan | Irbesartan | 41 | 17 |
| Amoxicillin | Amoxicillin | 40 | 30 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 14 |
| Mounjaro | Tirzepatide | 40 | 12 |
| Novolog Flexpen | Insulin Aspart | 40 | 13 |
| Cefuroxime | Cefuroxime Axetil | 39 | 33 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 13 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 37 | suppressed |
| Prolia | Denosumab | 36 | 25 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Restasis | Cyclosporine | 34 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 33 | 11 |
| Lumigan | Bimatoprost | 33 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 32 | 11 |
| Metronidazole | Metronidazole | 32 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 13 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Levofloxacin | Levofloxacin | 31 | 24 |
| Nitroglycerin | Nitroglycerin | 31 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 30 | 11 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 16 |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 26 | 23 |
| Valacyclovir | Valacyclovir Hcl | 26 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 25 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Colchicine | Colchicine | 24 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Nurtec Odt | Rimegepant Sulfate | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Ursodiol | Ursodiol | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Tadalafil | Tadalafil | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Telmisartan | Telmisartan | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | 17 |
| Sucralfate | Sucralfate | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Bicalutamide | Bicalutamide | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Rhopressa | Netarsudil Mesylate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $191.47 · 9 records | PFIZER INC. | APTIMA, BREZTRI, LEQVIO, Ozempic, RECORLEV, VYNDAMAX, VYNDAQEL | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error